Compare TBPH & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | HTD |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 916.6M |
| IPO Year | 2013 | 2003 |
| Metric | TBPH | HTD |
|---|---|---|
| Price | $13.86 | $25.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 782.6K | 56.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $70.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $20.31 |
| 52 Week High | $21.03 | $26.12 |
| Indicator | TBPH | HTD |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 52.70 |
| Support Level | $13.41 | $24.30 |
| Resistance Level | $14.76 | $25.72 |
| Average True Range (ATR) | 0.58 | 0.26 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 11.29 | 30.51 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.